{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T12:06:58Z","timestamp":1778846818412,"version":"3.51.4"},"reference-count":34,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:00:00Z","timestamp":1778716800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>Background: South Korea continues to report a considerable burden of drug-resistant tuberculosis (TB). Bedaquiline-containing regimens are recommended for multidrug-resistant pulmonary TB, but evidence regarding the optimal treatment for extrapulmonary manifestations such as spinal TB remains limited. Case presentation: Herein, we report two cases of drug-resistant tuberculous spondylitis that were successfully managed using bedaquiline-containing regimens. Case 1 involved a 67-year-old man who was receiving chemotherapy for lymphoma and had a history of spinal TB treated 20 years earlier. The patient presented with dysphagia and upper limb weakness. Cervical magnetic resonance imaging revealed C4\u20135 spondylitis with an epidural abscess. He underwent surgical treatment, and Mycobacterium tuberculosis resistant to rifampin was isolated from cultured intraoperatively obtained tissue specimens. The patient received an antibiotic regimen consisting of bedaquiline, levofloxacin, linezolid, cycloserine, and clofazimine. Clinical and radiological improvements were achieved after 12 months of this treatment; bedaquiline was included in the regimen for the first 6 months, while the other agents were continued for the entire course. Case 2 involved a 71-year-old man with T12\u2013L2 spondylitis and a left psoas abscess. Tissue culture confirmed Mycobacterium tuberculosis resistant to isoniazid, rifampin, and ethambutol. The patient was started on the same bedaquiline-containing regimen. Clinical and radiological improvements were observed after 18 months of this therapy, including 6 months of bedaquiline. Conclusions: Our clinical experiences suggest that bedaquiline-containing regimens represent a feasible and effective therapeutic option for drug-resistant tuberculous spondylitis. Larger studies are warranted to establish the optimal management strategies for extrapulmonary drug-resistant TB infections.<\/jats:p>","DOI":"10.3390\/antibiotics15050493","type":"journal-article","created":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T10:33:21Z","timestamp":1778841201000},"page":"493","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Drug-Resistant Tuberculous Spondylitis Treated with Bedaquiline-Containing Regimens in South Korea: Two Case Reports"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-8027-5533","authenticated-orcid":false,"given":"Keon Young","family":"Lee","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases, Keimyung University Dongsan Hospital, Keimyung University School of Medicine, Keimyung University, Daegu 42601, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miri","family":"Hyun","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Keimyung University Dongsan Hospital, Keimyung University School of Medicine, Keimyung University, Daegu 42601, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2788-1392","authenticated-orcid":false,"given":"Ji Yeon","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Keimyung University Dongsan Hospital, Keimyung University School of Medicine, Keimyung University, Daegu 42601, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9125-7156","authenticated-orcid":false,"given":"Hyun ah","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Keimyung University Dongsan Hospital, Keimyung University School of Medicine, Keimyung University, Daegu 42601, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,5,14]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"96S","DOI":"10.1177\/2192568218769053","article-title":"Spinal Tuberculosis: Current Concepts","volume":"8","author":"Rajasekaran","year":"2018","journal-title":"Glob. Spine J."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1179\/2045772311Y.0000000023","article-title":"Spinal tuberculosis: A review","volume":"34","author":"Garg","year":"2011","journal-title":"J. Spinal Cord Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1302\/0301-620X.92B7.24668","article-title":"Tuberculosis of the spine: A fresh look at an old disease","volume":"92","author":"Jain","year":"2010","journal-title":"J. Bone Jt. Surg. Br."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"77","DOI":"10.5495\/wjcid.v5.i4.77","article-title":"Epidemiological perspective of drug resistant extrapulmonary tuberculosis","volume":"5","author":"Singh","year":"2015","journal-title":"World J. Clin. Infect. Dis."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"100","DOI":"10.4103\/ortho.IJOrtho_306_17","article-title":"Drug-resistant Spinal Tuberculosis","volume":"52","author":"Jain","year":"2018","journal-title":"Indian J. Orthop."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.jcot.2020.07.028","article-title":"Drug-resistant spinal tuberculosis\u2014Current concepts, challenges, and controversies","volume":"11","author":"Soundararajan","year":"2020","journal-title":"J. Clin. Orthop. Trauma"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1183\/13993003.00724-2015","article-title":"Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis","volume":"47","author":"Pym","year":"2016","journal-title":"Eur. Respir. J."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Omoteso, O.A., Fadaka, A.O., Walker, R.B., and Khamanga, S.M. (2025). Innovative Strategies for Combating Multidrug-Resistant Tuberculosis: Advances in Drug Delivery Systems and Treatment. Microorganisms, 13.","DOI":"10.20944\/preprints202503.0157.v1"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1056\/NEJMoa2117166","article-title":"A 24-Week, All-Oral Regimen for Rifampin-Resistant Tuberculosis","volume":"387","author":"Berry","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_10","first-page":"e20240295","article-title":"Bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaLM) for multidrug- or rifampin-resistant tuberculosis: A systematic review","volume":"50","author":"Silva","year":"2025","journal-title":"J. Bras. Pneumol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"100433","DOI":"10.1016\/j.jctube.2024.100433","article-title":"Concomitant bedaquiline and delamanid therapy in patients with drug-resistant extra-pulmonary tuberculosis in Mumbai, India","volume":"35","author":"Mongia","year":"2024","journal-title":"J. Clin. Tuberc. Other Mycobact. Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"102701","DOI":"10.1016\/j.bjid.2022.102701","article-title":"Use of bedaquiline in spinal osteomyelitis and soft tissue abscess caused by multidrug-resistant Mycobacterium tuberculosis: A case report","volume":"26","author":"Fiore","year":"2022","journal-title":"Braz. J. Infect. Dis."},{"key":"ref_13","first-page":"55","article-title":"Review of the Global Burden of Tuberculosis in 2023: Insights from the WHO Global Tuberculosis Report 2024","volume":"18","author":"Lee","year":"2025","journal-title":"Jugan Geongang Gwa Jilbyeong"},{"key":"ref_14","unstructured":"World Health Organization (2025). Global Tuberculosis Report 2025, World Health Organization. Available online: https:\/\/www.who.int\/teams\/global-programme-on-tuberculosis-and-lung-health\/tb-reports\/global-tuberculosis-report-2025."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e60","DOI":"10.3346\/jkms.2026.41.e60","article-title":"Drug Resistance in Extrapulmonary Tuberculosis in Korea, 2010\u20132019: A Comparison With Pulmonary Tuberculosis","volume":"41","author":"Kim","year":"2026","journal-title":"J. Korean Med. Sci."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1007\/s00586-012-2331-y","article-title":"Bone and joint tuberculosis","volume":"22","year":"2013","journal-title":"Eur. Spine J."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"001003.v4","DOI":"10.1099\/acmi.0.001003.v4","article-title":"Bilateral tuberculous psoas abscesses in an immunocompetent patient: A case report and review of the literature","volume":"7","author":"Laatiris","year":"2025","journal-title":"Access Microbiol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e05823","DOI":"10.1002\/ccr3.5823","article-title":"Isolated psoas abscess caused by Mycobacterium tuberculosis: A rare case report","volume":"10","author":"Vasigh","year":"2022","journal-title":"Clin. Case Rep."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"111039","DOI":"10.1016\/j.ijscr.2025.111039","article-title":"Pott\u2019s disease presenting with bilateral psoas abscesses in a resource-poor setting: Case report and literature review","volume":"128","author":"Ayen","year":"2025","journal-title":"Int. J. Surg. Case Rep."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.jgar.2021.06.009","article-title":"Prevalence of drug resistance-conferring mutations associated with isoniazid- and rifampicin-resistant Mycobacterium tuberculosis in Ethiopia: A systematic review and meta-analysis","volume":"26","author":"Reta","year":"2021","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1093\/jac\/dku161","article-title":"Detection of mutations associated with isoniazid resistance in multidrug-resistant Mycobacterium tuberculosis clinical isolates","volume":"69","author":"Jagielski","year":"2014","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Seifert, M., Catanzaro, D., Catanzaro, A., and Rodwell, T.C. (2015). Genetic Mutations Associated with Isoniazid Resistance in Mycobacterium tuberculosis: A Systematic Review. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0119628"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jctube.2017.06.001","article-title":"Prevalence of mutations in genes associated with rifampicin and isoniazid resistance in Mycobacterium tuberculosis clinical isolates","volume":"8","author":"Muthaiah","year":"2017","journal-title":"J. Clin. Tuberc. Other Mycobact. Dis."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1016\/S1473-3099(24)00263-9","article-title":"Targeted next-generation sequencing to diagnose drug-resistant tuberculosis: A systematic review and meta-analysis","volume":"24","author":"Schwab","year":"2024","journal-title":"Lancet Infect. Dis."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e0409823","DOI":"10.1128\/spectrum.04098-23","article-title":"Comparison of targeted next-generation sequencing and the Xpert MTB\/RIF assay for detection of Mycobacterium tuberculosis in clinical isolates and sputum specimens","volume":"12","author":"Zhang","year":"2024","journal-title":"Microbiol. Spectr."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"6977","DOI":"10.1128\/AAC.01291-16","article-title":"Bedaquiline Targets the \u03b5 Subunit of Mycobacterial F-ATP Synthase","volume":"60","author":"Kundu","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e25091","DOI":"10.1002\/jcla.25091","article-title":"A Narrative Review of Bedaquiline and Delamanid: New Arsenals Against Multidrug-Resistant and Extensively Drug-Resistant Mycobacterium tuberculosis","volume":"38","author":"Sirous","year":"2024","journal-title":"J. Clin. Lab. Anal."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"25273","DOI":"10.1074\/jbc.M803899200","article-title":"Diarylquinolines Are Bactericidal for Dormant Mycobacteria as a Result of Disturbed ATP Homeostasis","volume":"283","author":"Koul","year":"2008","journal-title":"J. Biol. Chem."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Angula, K.T., Legoabe, L.J., and Beteck, R.M. (2021). Chemical Classes Presenting Novel Antituberculosis Agents Currently in Different Phases of Drug Development: A 2010\u20132020 Review. Pharmaceuticals, 14.","DOI":"10.3390\/ph14050461"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa2119430","article-title":"Bedaquiline-Pretomanid-Linezolid Regimens for Drug-Resistant Tuberculosis","volume":"387","author":"Conradie","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_31","unstructured":"World Health Organization (2022). WHO Consolidated Guidelines on Tuberculosis: Module 4: Treatment\u2014Drug-Resistant Tuberculosis Treatment, 2022 Update, World Health Organization. Available online: https:\/\/www.who.int\/publications\/i\/item\/9789240063129."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1701462","DOI":"10.1183\/13993003.01462-2017","article-title":"Cardiac safety of bedaquiline: A systematic and critical analysis of the evidence","volume":"50","author":"Pontali","year":"2017","journal-title":"Eur. Respir. J."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Huddart, S., Geocaniga-Gaviola, D.M., Crowder, R., Lim, A.R., Lopez, E., Valdez, C.L., Berger, C.A., Destura, R., Kato-Maeda, M., and Cattamanchi, A. (2022). Adherence trajectory as an on-treatment risk indicator among drug-resistant TB patients in the Philippines. PLoS ONE, 17.","DOI":"10.1101\/2022.05.04.22274664"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1002\/psp4.12147","article-title":"Population Pharmacokinetics of Bedaquiline and Metabolite M2 in Patients With Drug-Resistant Tuberculosis: The Effect of Time-Varying Weight and Albumin","volume":"5","author":"Svensson","year":"2016","journal-title":"CPT Pharmacomet. Syst. Pharmacol."}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/15\/5\/493\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T11:08:37Z","timestamp":1778843317000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/15\/5\/493"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,14]]},"references-count":34,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["antibiotics15050493"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics15050493","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,14]]}}}